Pricing Availability   Qty
Description: COMT inhibitor; also inhibits transthyretin aggregation
Alternative Names: Tasmar,Ro 40-7592
Chemical Name: (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
Purity: ≥99% (HPLC)
Literature (1)

Biological Activity for Tolcapone

Tolcapone is a COMT inhibitor. Inhibits both brain and peripheral COMT. Also binds transthyretin (TTR) with high affinity (Kd1 and Kd2 values are 21 and 58 nM, respectively). Inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicity in vitro. Stabilizes TTR in mice and humans in vivo. Orally bioavailable.

Technical Data for Tolcapone

M. Wt 273.24
Formula C14H11NO5
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 134308-13-7
PubChem ID 4659569
Smiles OC1=C(O)C([N+]([O-])=O)=CC(C(C2=CC=C(C)C=C2)=O)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Tolcapone

Solvent Max Conc. mg/mL Max Conc. mM
ethanol 27.32 100
DMSO 27.32 100

Preparing Stock Solutions for Tolcapone

The following data is based on the product molecular weight 273.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.66 mL 18.3 mL 36.6 mL
5 mM 0.73 mL 3.66 mL 7.32 mL
10 mM 0.37 mL 1.83 mL 3.66 mL
50 mM 0.07 mL 0.37 mL 0.73 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for Tolcapone

References are publications that support the biological activity of the product.

Sant'Anna et al (2016) Repositioning tolc. as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat.Commun. 7 10787 PMID: 26902880

Männistö et al (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br.J.Pharmacol. 105 569 PMID: 1628144

If you know of a relevant reference for Tolcapone, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Catechol O-Methyltransferase Inhibitors

Keywords: Tolcapone, Tolcapone supplier, catechol, O-methyl, transferase, inhibitors, inhibits, COMT, orally, bioavailable, high, affinity, TTR, binding, transthyretin, aggregation, Ro40-7592, Tasmar, Ro, 40-7592, Catechol, O-Methyltransferase, 5864, Tocris Bioscience

Citations for Tolcapone

Citations are publications that use Tocris products.

Currently there are no citations for Tolcapone. Do you know of a great paper that uses Tolcapone from Tocris? Please let us know.

Reviews for Tolcapone

There are currently no reviews for this product. Be the first to review Tolcapone and earn rewards!

Have you used Tolcapone?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.